Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56.Key topics included:• The design and findings of the DESTINY-Breast09 trial• Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane)• The implications of these findings for clinical practice• The role of maintenance therapy and the potential for personalized treatment strategies• Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease)Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients.Follow us on social media:•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers•⁠ Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!#HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers